Yoshimasa Shiraishi, Junji Kishimoto, Shunichi Sugawara, Hideaki Mizutani, Haruko Daga, Koichi Azuma, Hirotaka Matsumoto, Osamu Hataji, Kazumi Nishino, Masahide Mori, Takehito Shukuya, Haruhiro Saito, Motoko Tachihara, Hidetoshi Hayashi, Asuka Tsuya, Kazushige Wakuda, Noriko Yanagitani, Tomohiro Sakamoto, Satoru Miura, Akito Hata, Morihito Okada, Toshiyuki Kozuki, Yuki Sato, Taishi Harada, Koichi Takayama, Nobuyuki Yamamoto, Kazuhiko Nakagawa, Isamu Okamoto
IMPORTANCE: The combination of an antibody to programmed cell death-1 (PD-1) or to its ligand (PD-L1) with chemotherapy is the standard first-line treatment for metastatic non-small cell lung cancer (NSCLC). Bevacizumab is expected to enhance the efficacy not only of chemotherapy but also of PD-1/PD-L1 antibodies through blockade of vascular endothelial growth factor-mediated immunosuppression, but further data are needed to support this. OBJECTIVE: To evaluate the efficacy and safety of bevacizumab administered with platinum combination therapy and atezolizumab in patients with advanced nonsquamous NSCLC...
March 1, 2024: JAMA Oncology